Markets
Tech
Media
Success
Video
Markets
Premarkets
Dow
After-Hours
Market Movers
Fear & Greed
World Markets
Investing
Markets Now
Before the Bell
Leading Indicator
Global Energy Challenge
Economy
Energy
Tech
Innovate
Gadget
Mission: Ahead
Upstarts
Business Evolved
Work Transformed
Innovative Cities
Unhackable
Media
Reliable Sources
Success
Boss Files
Fresh Money
Cars
Homes
Biz + Leisure
Center Piece
Perspectives
Video
International
Switzerland
India
Davos
Passion to Portfolio
On: Germany
More
Newsletters
About Us
Accessibility and CC
U.S.
World
Politics
Business
Opinion
Health
Entertainment
Tech
Style
Travel
Sports
Video
Shop
VR
More...
Follow CNN Business
Do Not Sell
Ligand Pharmaceuticals Inc
(NASDAQ:LGND)
68.61
Delayed Data
As of Mar 23
+0.98
/
+1.45%
Today’s Change
45.25
Today
|||
52-Week Range
83.95
+2.71%
Year-to-Date
Quote
Profile
News
Charts
Forecasts
Financials
Shareholders
Competitors
Latest LGND News
|
Press Releases
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
Mar 23 / Zacks.com - Paid Partner Content
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
Mar 20 / Zacks.com - Paid Partner Content
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
Mar 23 / Zacks.com - Paid Partner Content
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
Mar 20 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
Mar 23 / Zacks.com - Paid Partner Content
Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion
Mar 17 / Zacks.com - Paid Partner Content
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
Mar 22 / Zacks.com - Paid Partner Content
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
Mar 17 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
Mar 22 / Zacks.com - Paid Partner Content
How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%
Mar 17 / Zacks.com - Paid Partner Content
Gilead (GILD) Exercises Option to License Nurix's Candidate
Mar 21 / Zacks.com - Paid Partner Content
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
Mar 16 / Zacks.com - Paid Partner Content
4 Biotech Stocks to Consider for Your Portfolio in 2023
Mar 21 / Zacks.com - Paid Partner Content
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
Mar 16 / Zacks.com - Paid Partner Content
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Mar 21 / Zacks.com - Paid Partner Content